Skip to main content

Table 3 Univariate Cox PH regression models for local/regional recurrence(LRR)-free survival (Number = 819).

From: Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy

Variable LRR-free
(Number = 800)
LRR (Number = 19) HR (95%CI) P-value
Age at diagnosis     
   > 50 522 7 reference  
   < 50 278 12 3.22 (1.28 to 8.33) 0.01
T stage     
   T1 604 9 reference  
   T2 187 8 2.95 (1.14-7.64) 0.03
   T3 9 2 19.8 (4.24-92.3) < 0.01
Pathologic stage     
   I 450 4 Reference  
   IIA and IIB 335 11 3.74 (1.19-11.7) 0.02
   IIIA, IIIB, IIIC and IV 15 4 31.8 (7.94- 127) < 0.01
Number of positive lymph nodes     
   0 579 7 reference  
   1-3 209 10 3.94 (1.50-10.3) 0.01
   > 4 8 2 23.3 (4.83- 112) < 0.01
Modified Black's nuclear grade     
   3 versus 1,2    6.93 (2.30-20.88) < 0.01
ER or PR     
   Negative 137 11 reference  
   Positive 648 8 0.15 (0.06-0.38) < 0.01
HER2+     
   Negative 653 15 reference  
   Positive 105 4 1.64 (0.54-4.94) 0.38
Lymphovascular invasion     
   Negative 555 9 reference  
   Positive 127 10 5.08 (2.06-12.5) < 0.01
Received trastuzumab (in HER2+ patients)     
   No 78 2 reference  
   Yes 26 2 3.87 (0.53-28.1) 0.18
Systemic therapy     
   No 141 3 reference  
   Yes 658 16 1.11 (0.32-3.80) 0.87
Constructed Subtype     
   HR+/HER2- 569 5 reference  
   HR+/HER2+ 54 3 6.25 (1.49-26.2) 0.01
   HR-/HER2+ 50 1 2.24 (0.26-19.2) 0.46
   HR-/HER2- 84 10 13.6 (4.63-39.7) < 0.01
  1. CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth receptor 2; PR, progesterone receptor.